Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics

The use of all trans-retinoic acid (ATRA) and combination chemotherapy has made acute promyelocytic leukemia (APL) a potentially curable leukemia. Late sequelae of the treatment of APL have therefore become an important consideration in the overall treatment strategy. We report a patient with APL wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahoo, Ranjit Kumar, Kumar, Lalit, Kumar, Rajive, Sharma, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932606/
https://www.ncbi.nlm.nih.gov/pubmed/24604968
http://dx.doi.org/10.4103/0971-5851.125261
Descripción
Sumario:The use of all trans-retinoic acid (ATRA) and combination chemotherapy has made acute promyelocytic leukemia (APL) a potentially curable leukemia. Late sequelae of the treatment of APL have therefore become an important consideration in the overall treatment strategy. We report a patient with APL who achieved complete clinical and molecular remission after treatment with daunorubicin and ATRA. Three years later, she developed acute myeloid leukemia (AML), M2 subtype without any evidence of relapse of the APL clone. Karyotypic analysis showed a normal female karyotype.

Ejemplares similares